Imatinib - Novartis

Drug Profile

Imatinib - Novartis

Alternative Names: CGP 57148; CGP 57148B; CTI 571; Gleevec; Glivec; Imatinib mesilate; Imatinib mesylate; QTI 571; Ruvise; STI 571

Latest Information Update: 14 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Dermatofibrosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic mastocytosis
  • Phase II Acute myeloid leukaemia; Fibroma; Malignant melanoma; Non-Hodgkin's lymphoma; Prostate cancer
  • No development reported Mesothelioma
  • Discontinued Diffuse scleroderma; Glioblastoma; Non-small cell lung cancer; Polycythaemia vera; Pulmonary arterial hypertension; Sarcoma; Small cell lung cancer; Systemic scleroderma

Most Recent Events

  • 28 Aug 2018 Novartis completes a phase I/II trial for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT00667953)
  • 06 Jul 2018 Novartis Pharmaceuticals plans a phase II trial for Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) (NCT03578367)
  • 11 Jun 2018 University Hospital Freiburg and Novartis suspends the phase III DECLINE trial for Chronic myeloid leukaemia in Germany, due to very slow recruitment rate (NCT02174445) (EudraCT2013-000077-68)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top